New board member joins AFFiRiS AGVienna, 9. September 2014 – AFFiRiS AG today announced the appointment of Oliver Siegel as a new member of the Executive Management Board. He will take over responsibility for Business Development, Finance and Administration. The appointment of the international experienced transaction expert extends the know-how of the board with a focus on partnering and business operations. Oliver Siegel will expend his experience gained at leading international investment banks to focus on the partnering of the AFFiRiS programs, whose clinical data have been published in the last few months.
Oliver Siegel has been appointed as the new Chief Operating Officer (COO) of AFFiRiS AG. In this position, he is responsible for the company’s business development and its administrative functions. Oliver Siegel has handled over 100 corporate acquisitions and disposals, cooperation agreements, IPOs as well as other capital markets transactions for the pharmaceutical, biotech and health care industry and is considered as one of its most experienced experts.
Before starting at AFFiRiS, Oliver Siegel headed the pharma practice at Rothschild investment bank in London, where he previously worked as Head of European Pharmaceutical Sector. He advised Roche in various M&A and finance transactions, such as the acquisition of Genentech. Furthermore, he advised on several IPOs of high-profile biotech companies like Serono or Speedel. Prior to this, he was Head of Healthcare Investment Banking at HSBC plc. in London.
The expert on M&A and Corporate Finance comments on his new role: “In the industry, AFFiRiS is one of the leading companies in the field of therapeutic vaccines – this is without a doubt one of the most exciting treatment approaches for chronic diseases existing at the moment. I am delighted to contribute my years of experience in the pharmaceutical and biotech industry to help finding new partners for the further development of AFFiRiS programs.”
AFFiRiS recently published phase II data of an Alzheimer’s drug candidate in clinical development and phase I data of a Parkinson’s vaccine candidate, the first substance targeted at α-synuclein, that has successfully finished a phase I trial. Α-synuclein is a protein that is attributed to playing a key role in the pathogenic progress of neurodegenerative diseases such as Parkinson’s or Alzheimer’s. The development of AFFiRiS Parkinson’s vaccines enjoys the continuing support of the renowned Michael J. Fox Foundation.
Walter Schmidt, CEO and co-founder of AFFiRiS, on these successes and their significance for the company: “Our success in the development of therapeutic vaccines for diseases with unmet medical needs and attractive market volumes leads to a constantly increasing interest of the pharmaceutical industry. The extensive knowledge of Oliver Siegel will allow us to leverage this interest for our corporate strategy and to accelerate the development of life-enhancing treatments. I am very pleased to have him join our Executive Board of Management.”
About AFFiRiS AG (By: September 2014)
On the basis of its proprietary patented AFFITOME®-technology, AFFiRiS develops tailor-made therapeutic peptide vaccines against chronic diseases. Currently, there are 3 drug candidates against Alzheimer’s, Parkinson’s and MSA in clinical development. Further vaccine candidates against Lipid Lowering respectively Atherosclerosis, Diabetes, Psoriasis, Allergies, Asthma as well as for Huntington's are in preclinical development. Thus far, AFFiRiS has been able to attract funding of close to € 100m, especially from its main investors MIG AG from Munich/Germany and Santo VC, the family office of the Strüngmann-family. AFFiRiS currently employs 85 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria (www.affiris.com).
Contact AFFiRiS AG:
Mag. Julia Bock
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 – 303
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New board member joins AFFiRiS AG here
News-ID: 294949 • Views: 12076
More Releases from AFFiRiS AG
AFFiRiS AG successfully raises €10m equity financing
• € 10m additional capital raised • Strengthened management team, Günther Staffler appointed as Chief Technology Officer • Noel Barrett appointed as additional member of the supervisory board AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors and FCPB Affi GmbH. The Supervisory Board has appointed Günther Staffler as Chief Technology Officer. Noel Barrett has joined the Supervisory Board as of 15 June 2016. In
Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG
Vaccine Specialist AFFiRiS AG successfully completes Financing Round • € 10m additional capital raised • Supervisory Board appoints Oliver Siegel as Chief Executive Officer • Prof. Dr. Christoph Huber elected to Supervisory Board AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the
AFFiRiS AG: ALZHEIMER'S VACCINE AD02 ALREADY IN CLINICAL PHASE II
Vienna (Austria), 23. April 2010: AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a
Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing Vienna, November 18, 2009: AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of
More Releases for Oliver
New Oliver Wight Demand Management White Paper
Business improvement specialists, Oliver Wight have released a new white paper on managing demand. Authored by Oliver Wight Partner, Debbie Heaton, the white paper explains why organisations need sales and marketing to take ownership of the demand management process if they are to keep up with the competition. “In the current business environment it’s more important than ever that companies are consumer-driven; that means not only capturing and understanding demand, but
Oliver Wight Launches Annual European Conference
Business improvement specialists Oliver Wight have announced their inaugural European customer conference, to be held at the Sheraton Hotel, Brussels airport, on November 19th and 20th 2013. The conference, for Oliver Wight customers past and present, is free to attend by invitation. The event opens with a gala dinner for delegates and awards for those companies, which have achieved the Class A standard this year, followed by an inspirational after-dinner
Oliver Wight announce new Hong Kong office
Business Improvement specialists, Oliver Wight, have announced the opening of a new office in Hong Kong. The new office is part of the consultancy’s wider expansion across Asia. Oliver Wight are presenting at the inaugural S-Council Annual Congress in December and are holding an education academy in Singapore in January. Mike Reed, Managing Partner at the business improvement specialists says: “The Asian region is strong and growing rapidly, and we’re increasingly
Oliver Wight give Revlon Global Makeover
As part of its plans to increase globalisation, and following success in the UK and Europe, cosmetics giant Revlon is now rolling out its Oliver Wight Integrated Business Planning (IBP) programme across all regions. The decision to implement IBP on a global level was taken after seeing spectacular results within the European operation, where inventory was reduced by 50% whilst service levels rose to 98.5%. The IBP programme has paid dividends in
Metal Design Furniture Improve Oliver Chair Design
London, United Kingdom (14 April 2011) - Metal Design Furniture, an up-and-coming online retailer of metal beds, home accessories, fences, garden furniture and gazebos, have improved the design of their metal Oliver chairs in time for Spring with a few technological details that make all the difference when it comes to comfort!. Metal Design Furniture is celebrating the new season with an improved Oliver chair design. This includes the incorporation of
Oliver Wight lead Demand Planning Webcast
Business Improvement specialists, Oliver Wight, are leading a webcast on the ‘dos and don’ts of demand planning’ on Tuesday 22nd February 2011. The thirty minute webcast, which will be hosted by software provider, Oracle, and led by Oliver Wight Managing Partner, James Small, is designed to provide an introduction to senior executives and middle management on how best to sense, shape and respond to demand. “As we emerge from the